Inflectra is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat people with moderately to severely active rheumatoid arthritis. Inflectra is indicated for use in combination with methotrexate. Inflectra is also referred to by its drug name, infliximab-dyyb.
Inflectra is a biosimilar of Remicade. As defined by the FDA, a biosimilar is a biological product that is approved based on a showing that it is highly similar to an already-approved biological product.
Inflectra is considered a biologic disease-modifying antirheumatic drug (DMARD). It is a genetically engineered antibody used by the immune system to identify and neutralize substances. Inflectra is believed to work by attaching to tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks. Inflectra binds to TNF-α and prevents it from signaling the immune system to attack the connective tissues.
How do I take it?
Inflectra is administered as an intravenous infusion in a medical setting every eight weeks after initial loading doses.
Inflectra is available in vial form.
The FDA-approved label for Inflectra lists common side effects including respiratory tract infections, infusion-related reactions, headache, and abdominal pain.
Rare but serious side effects listed for Inflectra can include severe infections, increased risk for lymphoma and other cancers, hepatitis B virus reactivation, liver damage leading to liver failure, heart failure, low blood cell counts, lupus-like syndrome, and nerve damage..
For more details about this treatment, visit:
Inflectra — Pfizer
Inflectra — Drugs.com
We never share your personal information with anyone.